InsideTrading SEC Form 4 insider trades
← All clusters
KLRA

Kailera Therapeutics, Inc.

Limited buying: $326.8M bought (counted up to $5.0M); 5 distinct insiders. Holding it back: largest buyer: Kaplan Andrew T. (Director), 41% of the dollars.

AI summary Insiders and major 10% owners purchase shares at the $16 IPO price

48
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. <60 · limited buying
–
Since the cluster formed, vs benchmark

Score, not a recommendation.

Total bought$326.8M5 Form 4 purchases
Distinct insiders5open-market buyers
Insiders' average price$16.00no price on the purchase days
Cluster window2026-04-20single day · closed

partial dataAn input is missing, usually the market cap or the price history. A missing input counts as neutral in the score and is never estimated. Market cap is missing; missing inputs count as neutral in the score.

same price, one day All 5 purchases were at $16.00 on 2026-04-20. That pattern also occurs in IPO or conversion subscriptions, which are not open-market conviction buying.

Price and insider purchases

Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.

Loading price history…

How the score adds up

How each input is counted →
Points each input adds to the score, and how much of the points it could give it has
Input Strength Points
$326.8M bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. 100% +57
5 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. 70% +10
No CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. 0% +0
Stock 0% below its 1-year highHow far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. 0% +0
0 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. 100% +0
Routine or plan purchases: 0% of the dollarsThe share of the dollars in routine or plan purchases (a Rule 10b5-1 plan, dividend reinvestment, a regular cadence). All of it routine would take off 5.6 points. 100% +0
Largest buyer: Kaplan Andrew T. (Director), 41% of the dollarsThe share of the dollars bought by the largest buyer. Buying spread evenly keeps the points; one buyer paying for everything takes off 12.7. 74% -5
Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast.62
AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results.-14
Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation.48

Why are they buying?

AI · ipo_offering · catalyst credible · documented

Insiders and major institutional backers acquired shares directly in connection with the company's initial public offering at the established offering price.

Kailera Therapeutics closed a major upsized $625 million initial public offering priced at $16 per share on April 20, 2026, alongside the conversion of preferred stock into common stock.

Written by an earlier version of the AI review.

Transactions

5 Form 4 trades · 5 insiders Download CSV Up to 5,000 rows
Purchases in this cluster, grouped by insider, largest first
Date InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. Role Shares Price Value Flags Filing
2026-04-20 Kaplan Andrew T. history of Kaplan Andrew T.'s purchases Director 8,398,438 $16.00 $134.4M
offering
SEC filing for Kaplan Andrew T. (opens in a new tab)
2026-04-20 BAIN CAPITAL INVESTORS LLC history of BAIN CAPITAL INVESTORS LLC's purchases 10% owner 8,398,438 $16.00 $134.4M
offering
SEC filing for BAIN CAPITAL INVESTORS LLC (opens in a new tab)
2026-04-20 Bain Capital Life Sciences Investors, LLC history of Bain Capital Life Sciences Investors, LLC's purchases 10% owner 1,562,500 $16.00 $25.0M
offering
SEC filing for Bain Capital Life Sciences Investors, LLC (opens in a new tab)
2026-04-20 Koppel Adam history of Koppel Adam's purchases Director 1,562,500 $16.00 $25.0M
offering
SEC filing for Koppel Adam (opens in a new tab)
2026-04-20 RTW INVESTMENTS, LP history of RTW INVESTMENTS, LP's purchases 10% owner 500,000 $16.00 $8.0M
offering
SEC filing for RTW INVESTMENTS, LP (opens in a new tab)
Total $326.8M